Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease

European Journal of Medicinal Chemistry

Volumn 73, Issue , 2014, Pages 56-72

  González Naranjo, Pedro ^a   Pérez Macias, Natalia ^a   Campillo, Nuria E ^a   Pérez, Concepción ^a   Arán, Vicente J ^a   Girón, Rocio ^b   Sánchez Robles, Eva ^b   Martín, María Isabel ^b   Gómez Cañas, María ^c   García Arencibia, Moisés ^c   Fernández Ruiz, Javier ^c   Páez, Juan A ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Alzheimer's disease; Antioxidant; BuChE inhibitor; CB2R agonist; Drug design; Indazole ether; Multitarget drug

Indexed keywords

1 (2 DIISOPROPYLAMINOETHYL) 3 (1 NAPHTHYLMETHOXY)INDAZOLE; 1 (2 DIISOPROPYLAMINOETHYL) 3 (4 METHOXYBENZYLOXY) 5 NITROINDAZOLE; 1 (2 DIISOPROPYLAMINOETHYL) 3 (4 METHOXYBENZYLOXY)INDAZOLE; 1 (2 MORPHOLINOETHYL) 3 (2 NAPHTHYLMETHOXY) 5 NITROINDAZOLE; 1 (4 METHOXYBENZYL) 3 (4 METHOXYBENZYLOXY)INDAZOLE; 1 BENZYL 3 (2 NAPHTHYLMETHOXY) 5 NITROINDAZOLE; 1 BENZYL 3 BENZYLOXYINDAZOLE; 1 BENZYL 3 CYCLOHEXYLMETHOXY 5 NITROINDAZOLE; 3 (1 NAPHTHYLMETHOXY) 1 (1 NAPHTHYLMETHYL) 5 NITROINDAZOLE; 3 (1 NAPHTHYLMETHOXY) 1 (1-NAPHTHYLMETHYL)INDAZOLE; 3 (1 NAPHTHYLMETHOXY) 1 (2 PIPERIDINOETHYL)INDAZOLE; 3 (1 NAPHTHYLMETHOXY) 1 [2 (PYRROLIDIN 1 YL)ETHYL]INDAZOLE; 3 (1 NAPHTHYLMETHOXY) 5 NITRO 1 [2 (PYRROLIDIN 1 YL)ETHYL]INDAZOLE; 3 (2 NAPHTHYLMETHOXY) 1 (2 NAPHTHYLMETHYL) 5 NITROINDAZOLE; 3 (2 NAPHTHYLMETHOXY) 1 (2 PIPERIDINOETHYL)INDAZOLE; 3 (2 NAPHTHYLMETHOXY) 5 NITRO 1 (2 PIPERIDINOETHYL)INDAZOLE; 3 (2 NAPHTHYLMETHOXY) 5 NITRO 1 PENTYLINDAZOLE; 3 (4 METHOXYBENZYLOXY) 5 NITRO 1 PENTYLINDAZOLE; 3 (CYCLOHEXYLMETHOXY) 1 (CYCLOHEXYLMETHYL)INDAZOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 AMINO 1 BENZYL 3 BENZYLOXYINDAZOLE; 5 AMINO 3 (1 NAPHTHYLMETHOXY) 1 [2 (PYRROLIDIN 1 YL)ETHYL]INDAZOLE; 5 AMINO 3 (2 NAPHTHYLMETHOXY) 1 (2 PIPERIDINOETHYL)INDAZOLE; 5 BROMO 3 (2 NAPHTHYLMETHOXY) 1 (2 PIPERIDINOETHYL)INDAZOLE; 5 NITRO 1 (PENTYL) 3 (PENTYLOXY)INDAZOLE; CANNABINOID RECEPTOR AGONIST; CHOLINESTERASE INHIBITOR; INDAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR DOCKING;

ALZHEIMER'S DISEASE; ANTIOXIDANT; BUCHE INHIBITOR; CB2R AGONIST; DRUG DESIGN; INDAZOLE ETHER; MULTITARGET DRUG;

ALZHEIMER DISEASE; ANIMALS; BUTYRYLCHOLINESTERASE; CANNABINOID RECEPTOR AGONISTS; CHOLINESTERASE INHIBITORS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HORSES; HUMANS; INDAZOLES; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84891587375     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.11.026     Document Type: Article

References (71)

1. J.A. Claassen, and R.W. Jansen Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis J. Gerontol. A Biol. Sci. Med. Sci. 61 2006 267 271
2. E. Coulthard, V. Singh-Curry, and M. Husain Treatment of attention deficits in neurological disorders Curr. Opin. Neurol. 19 2006 613 618 (Pubitemid 44760447)
3. M. Villarroya, A.G. Garcia, J. Marco-Contelles, and M.G. Lopez An update on the pharmacology of galantamine Expert Opin. Investig. Drugs 16 2007 1987 1998 (Pubitemid 351403729)
4. H.W. Klafki, M. Staufenbiel, J. Kornhuber, and J. Wiltfang Therapeutic approaches to Alzheimer's disease Brain 129 2006 2840 2855 (Pubitemid 44684507)
5. M.A. Kamal, X. Qu, Q.S. Yu, D. Tweedie, H.W. Holloway, Y. Li, Y. Tan, and N.H. Greig Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis J. Neural Transm. 115 2008 889 898
6. R.M. Lane, S.G. Potkin, and A. Enz Targeting acetylcholinesterase and butyrylcholinesterase in dementia Int. J. Neuropsychopharmacol. 9 2006 101 124 (Pubitemid 43068340)
7. R. Annicchiarico, A. Federici, C. Pettenati, and C. Caltagirone Rivastigmine in Alzheimer's disease: cognitive function and quality of life Ther. Clin. Risk Manag. 3 2007 1113 1123
8. R. Bullock, and R. Lane Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase Curr. Alzheimer Res. 4 2007 277 293 (Pubitemid 47025426)
9. A. Castro, and A. Martinez Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease Mini Rev. Med. Chem. 1 2001 267 272
10. G.V. De Ferrari, M.A. Canales, I. Shin, L.M. Weiner, I. Silman, and N.C. Inestrosa A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation Biochemistry 40 2001 10447 10457 (Pubitemid 32816655)
11. N.C. Inestrosa, A. Alvarez, M.C. Dinamarca, T. Perez-Acle, and M. Colombres Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway Curr. Alzheimer Res. 2 2005 301 306 (Pubitemid 40980188)
12. P. Masson, M.T. Froment, C.F. Bartels, and O. Lockridge Asp7O in the peripheral anionic site of human butyrylcholinesterase Eur. J. Biochem. 235 1996 36 48 (Pubitemid 26045418)
13. P. Masson, W. Xie, M.T. Froment, V. Levitsky, P.L. Fortier, C. Albaret, and O. Lockridge Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates Biochim. Biophys. Acta 1433 1999 281 293 (Pubitemid 29369063)
14. S. Diamant, E. Podoly, A. Friedler, H. Ligumsky, O. Livnah, and H. Soreq Butyrylcholinesterase attenuates amyloid fibril formation in vitro Proc. Natl. Acad. Sci. U. S. A. 103 2006 8628 8633 (Pubitemid 43878071)
15. N.H. Greig, T. Utsuki, D.K. Ingram, Y. Wang, G. Pepeu, C. Scali, Q.S. Yu, J. Mamczarz, H.W. Holloway, T. Giordano, D. Chen, K. Furukawa, K. Sambamurti, A. Brossi, and D.K. Lahiri Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent Proc. Natl. Acad. Sci. U. S. A. 102 2005 17213 17218 (Pubitemid 41692709)
16. M. Bajda, N. Guzior, M. Ignasik, and B. Malawska Multi-target-directed ligands in Alzheimer's disease treatment Curr. Med. Chem. 18 2011 4949 4975
17. Y. Rook, K.U. Schmidtke, F. Gaube, D. Schepmann, B. Wunsch, J. Heilmann, J. Lehmann, and T. Winckler Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents J. Med. Chem. 53 2010 3611 3617
18. M. Incerti, L. Flammini, F. Saccani, G. Morini, M. Comini, M. Coruzzi, E. Barocelli, V. Ballabeni, and S. Bertoni Dual-acting drugs: an in vitro study of nonimidazole histamine H3 receptor antagonists combining anticholinesterase activity ChemMedChem 5 2010 1143 1149
19. L. Piazzi, A. Cavalli, F. Colizzi, F. Belluti, M. Bartolini, F. Mancini, M. Recanatini, V. Andrisano, and A. Rampa Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds Bioorg. Med. Chem. Lett. 18 2008 423 426
20. W. Huang, D. Lv, H. Yu, R. Sheng, S.C. Kim, P. Wu, K. Luo, J. Li, and Y. Hu Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease Bioorg. Med. Chem. 18 2010 5610 5615
21. M. Hieke, J. Ness, R. Steri, M. Dittrich, C. Greiner, O. Werz, K. Baumann, M. Schubert-Zsilavecz, S. Weggen, and H. Zettl Design, synthesis, and biological evaluation of a novel class of gamma-secretase modulators with PPARgamma activity J. Med. Chem. 53 2010 4691 4700
22. J.H. Lange, H.K. Coolen, M.A. van der Neut, A.J. Borst, B. Stork, P.C. Verveer, and C.G. Kruse Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism J. Med. Chem. 53 2010 1338 1346
23. N.E. Campillo, and J.A. Paez Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease Mini Rev. Med. Chem. 9 2009 539 559
24. S.H. Walter, and M. Halpern Cannabinoids and dementia: review of clinical and preclinical data Pharmaceuticals 3 2010 2689 2708
25. B.G. Ramirez, C. Blazquez, T. Gomez del Pulgar, M. Guzman, and M.L. de Ceballos Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation J. Neurosci. 25 2005 1904 1913 (Pubitemid 40289395)
26. J.H. Lee, G. Agacinski, J.H. Williams, G.K. Wilcock, M.M. Esiri, P.T. Francis, P.T. Wong, C.P. Chen, and M.K. Lai Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex Neurochem. Int. 57 2010 985 989
27. S. Kalifa, E.K. Polston, J.S. Allard, and K.F. Manaye Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe/PS1DeltaE9 double transgenic mice Brain Res. 376 2011 94 100
28. C. Benito, W.K. Kim, I. Chavarria, C.J. Hillard, K. Mackie, R.M. Tolon, K. Williams, and J. Romero A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis J. Neurosci. 25 2005 2530 2536 (Pubitemid 40365164)
29. C. Benito, E. Nunez, R.M. Tolon, E.J. Carrier, A. Rabano, C.J. Hillard, and J. Romero Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains J. Neurosci. 23 2003 11136 11141 (Pubitemid 37548949)
30. C. Benito, R.M. Tolon, M.R. Pazos, E. Nunez, A.I. Castillo, and J. Romero Cannabinoid CB2 receptors in human brain inflammation Br. J. Pharmacol. 153 2008 277 285
31. R.M. Tolon, E. Nunez, M.R. Pazos, C. Benito, A.I. Castillo, J.A. Martinez-Orgado, and J. Romero The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages Brain Res. 1283 2009 148 154
32. J.C. Ashton, and M. Glass The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration Curr. Neuropharmacol. 5 2007 73 80 (Pubitemid 47019422)
33. Y. Marchalant, F. Cerbai, H.M. Brothers, and G.L. Wenk Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats Neurobiol. Aging 29 2008 1894 1901
34. V.A. Campbell, and A. Gowran Alzheimer's disease; taking the edge off with cannabinoids? Br. J. Pharmacol. 152 2007 655 662 (Pubitemid 350034982)
35. N.G. Milton Phosphorylated amyloid-beta: the toxic intermediate in alzheimer's disease neurodegeneration Subcell. Biochem. 38 2005 381 402
36. J. Ehrhart, D. Obregon, T. Mori, H. Hou, N. Sun, Y. Bai, T. Klein, F. Fernandez, J. Tan, and R.D. Shytle Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation J. Neuroinflammation 2 2005 29
37. P. Gonzalez-Naranjo, N.E. Campillo, C. Perez, and J.A. Paez Multitarget cannabinoids as novel strategy for Alzheimer disease Curr. Alzheimer Res. 10 2013 229 239
38. J.A. Páez, N.E. Campillo, P. González-Naranjo, C. Pérez, V.J. Arán, M.I. Martin Fontelles, R. Girón, E.M. Sánchez, Preparation of 3-Indazolyl Ethers with Cannabinoid and/or Cholinergic Properties Useful for Treating Various Diseases, Universidad Rey Juan Carlos, Spain, ES 2378139 (Oct. 1, 2009), WO 2011039388 (Sep 30, 2010).
39. S. Rizzo, A. Tarozzi, M. Bartolini, G. Da Costa, A. Bisi, S. Gobbi, F. Belluti, A. Ligresti, M. Allara, J.P. Monti, V. Andrisano, V. Di Marzo, P. Hrelia, and A. Rampa 2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents Eur. J. Med. Chem. 58 2012 519 532
40. C. Montero, N.E. Campillo, P. Goya, and J.A. Paez Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study Eur. J. Med. Chem. 40 2005 75 83 (Pubitemid 40092380)
41. K. Pfannstiel, and J. Janecke Representation of o-hydrazino-benzoic acids and indazolones by reduction of diazotated anthranilic acids with sulphuric acid Chem. Ber. 75 1942 1096 1107
42. V.J. Arán, M. Flores, P. Munoz, J.A. Paez, P. SanchezVerdu, and M. Stud Analogues of cytostatic, fused indazolinones: synthesis, conformational analysis and cytostatic activity against HeLa cells of some 1-substituted indazolols, 2-substituted indazolinones, and related compounds Liebigs Ann. 1996 683 691 (Pubitemid 126804329)
43. L. Baiocchi, G. Corsi, and G. Palazzo Synthesis, properties and reactions of 1H-indazol-3-ols and 1-2-dihydro-3h-indazol-3-ones Synthesis-Stuttgart 1978 633 648
44. P. Bruneau, C. Delvare, M.P. Edwards, and R.M. McMillan Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity J. Med. Chem. 34 1991 1028 1036
45. M.C. Vega, M. Rolon, A. Montero-Torres, C. Fonseca-Berzal, J.A. Escario, A. Gomez-Barrio, J. Galvez, Y. Marrero-Ponce, and V.J. Aran Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug Eur. J. Med. Chem. 58 2012 214 227
46. M.R. Lauwiner, and R.P. Wissmann Reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide hydroxide catalyst. I. The reduction of monosubstituted nitrobenzenes with hydrazine hydrate in the presence of ferrihydrite Appl. Catal. A Gen. 172 1998 7
47. G.L. Ellman, K.D. Courtney, V. Andres Jr., and R.M. Feather-Stone A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7 1961 88 95
48. M.L. Bolognesi, M. Bartolini, A. Cavalli, V. Andrisano, M. Rosini, A. Minarini, and C. Melchiorre Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues J. Med. Chem. 47 2004 5945 5952 (Pubitemid 39507336)
49. E. Giacobini Cholinesterases: new roles in brain function and in Alzheimer's disease Neurochem. Res. 28 2003 515 522 (Pubitemid 36314842)
50. H.A. Grigoryan, A.A. Hambardzumyan, M.V. Mkrtchyan, V.O. Topuzyan, G.P. Halebyan, and R.S. Asatryan alpha,beta-Dehydrophenylalanine choline esters, a new class of reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase Chem. Biol. Interact. 171 2008 108 116 (Pubitemid 350191848)
51. GraphPad-Prism 2013 GraphPad Software San Diego, CA, USA
52. M. Bartolini, C. Bertucci, V. Cavrini, and V. Andrisano beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies Biochem. Pharmacol. 65 2003 407 416 (Pubitemid 36084557)
53. C. Cano, P. Goya, J.A. Paez, R. Giron, E. Sanchez, and M.I. Martin Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity Bioorg. Med. Chem. 15 2007 7480 7493 (Pubitemid 47539131)
54. J. Cumella, L. Hernandez-Folgado, R. Giron, E. Sanchez, P. Morales, D.P. Hurst, M. Gomez-Canas, M. Gomez-Ruiz, D.C. Pinto, P. Goya, P.H. Reggio, M.I. Martin, J. Fernandez-Ruiz, A.M. Silva, and N. Jagerovic Chromenopyrazoles: non-psychoactive and selective CB(1) cannabinoid agonists with peripheral antinociceptive properties ChemMedChem 7 2012 452 463
55. R.G. Pertwee, L.A. Stevenson, D.B. Elrick, R. Mechoulam, and A.D. Corbett Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine Br. J. Pharmacol. 105 1992 980 984
56. A. Thomas, and R.G. Pertwee The bioassay of cannabinoids using the mouse isolated vas deferens Methods Mol. Med. 123 2006 191 207
57. B. Ou, M. Hampsch-Woodill, and R.L. Prior Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe J. Agric. Food Chem. 49 2001 4619 4626 (Pubitemid 32988695)
58. A. Davalos, C. Gomez-Cordoves, and B. Bartolome Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay J. Agric. Food. Chem. 52 2004 48 54
59. SYBYL 7.2, Tripos International, 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA.
60. J. Ramos, V.L. Cruz, J. Martinez-Salazar, N.E. Campillo, and J.A. Paez Dissimilar interaction of CB1/CB2 with lipid bilayers as revealed by molecular dynamics simulation Phys. Chem. Chem. Phys. 13 2011 3660 3668
61. K. Palczewski, T. Kumasaka, T. Hori, C.A. Behnke, H. Motoshima, B.A. Fox, I. Le Trong, D.C. Teller, T. Okada, R.E. Stenkamp, M. Yamamoto, and M. Miyano Crystal structure of rhodopsin: a G protein-coupled receptor Science 289 2000 739 745 (Pubitemid 30650186)
62. A. Poso, and J.W. Huffman Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands Br. J. Pharmacol. 153 2008 335 346
63. G. Kryger, M. Harel, K. Giles, L. Toker, B. Velan, A. Lazar, C. Kronman, D. Barak, N. Ariel, A. Shafferman, I. Silman, and J.L. Sussman Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II Acta Crystallogr. D Biol. Crystallogr. 56 2000 1385 1394
64. Y. Nicolet, O. Lockridge, P. Masson, J.C. Fontecilla-Camps, and F. Nachon Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products J. Biol. Chem. 278 2003 41141 41147 (Pubitemid 37280939)
65. P. Lavigne, J.R. Bagu, R. Boyko, L. Willard, C.F. Holmes, and B.D. Sykes Structure-based thermodynamic analysis of the dissociation of protein phosphatase-1 catalytic subunit and microcystin-LR docked complexes Protein Sci. 9 2000 252 264 (Pubitemid 30126998)
66. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
67. G. Griffin, Q. Tao, and M.E. Abood Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor J. Pharmacol. Exp. Ther. 292 2000 886 894 (Pubitemid 30136579)
68. J. Hughes, H.W. Kosterlitz, and F.M. Leslie Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antogonist potencies of narcotic analgesics Br. J. Pharmacol. 53 1975 371 381
69. P.A. Halgren Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 J. Comput. Chem. 17 1996 450 519
70. P.A. Halgren Merck molecular force field. 2. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions J. Comput. Chem. 17 1996 520 552
71. V. Sobolev, A. Sorokine, J. Prilusky, E.E. Abola, and M. Edelman Automated analysis of interatomic contacts in proteins Bioinformatics 15 1999 327 332 (Pubitemid 29213759)